We are live on ! Find out more
CRMD icon

CorMedix

79 hedge funds and large institutions have $55M invested in CorMedix in 2021 Q3 according to their latest regulatory filings, with 11 funds opening new positions, 24 increasing their positions, 21 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

61% more call options, than puts

Call options by funds: $938K | Put options by funds: $581K

14% more repeat investments, than reductions

Existing positions increased: 24 | Existing positions reduced: 21

10% more first-time investments, than exits

New positions opened: 11 | Existing positions closed: 10

1.14% more ownership

Funds ownership: 29.86%31% (+1.1%)

0% more funds holding

Funds holding: 7979 (0)

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

29% less capital invested

Capital invested by funds: $78M → $55M (-$23M)

Holders
79
Holders Change
Holders Change %
0%
% of All Funds
1.38%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.02%
New
11
Increased
24
Reduced
21
Closed
10
Calls
$938K
Puts
$581K
Net Calls
+$357K
Net Calls Change
-$1.1M

CRMD Hedge Fund Activity: Q3 2021 in Review

79 of the 5,728 institutional investors tracked by Wall St. Rank reported a position in CorMedix (CRMD) for Q3 2021, worth a combined $55M — down 29% from $78M a quarter earlier.

Buyers outnumbered sellers: 11 funds opened new CRMD positions and 10 closed out — a net gain of 1 holder — while 24 added to existing stakes and 21 trimmed.

The largest buyer was Nomura Holdings, opening a new position worth an estimated $2.54M. The largest seller was Oxford Financial Group, exiting entirely with an estimated $418K sold.

  • 79 institutional investors held CorMedix (CRMD) as of Q3 2021, unchanged from Q2 2021.
  • Funds reported $55M of CorMedix stock for Q3 2021, down 29% quarter-over-quarter.
  • 11 funds opened new CorMedix positions in Q3 2021 and 10 closed out, a net change of +1 holder.
  • The largest CorMedix buyer in Q3 2021 was Nomura Holdings, an estimated $2.54M added.
  • The largest CorMedix seller in Q3 2021 was Oxford Financial Group, an estimated $418K sold.

Based on aggregated 13F filings for Q3 2021.